8th Conference on Retroviruses and Opportunistic Infections Chicago, IL - February 4 - 8, 2001

Conf Retroviruses Opportunistic Infect 2001 Feb 4-8; 8:47 (abstract no. 14)

J. Eron¹, T. Merigan², M. Kilby³, B. Yangco⁴, J. Gleavy⁶, P. Rusnak⁶, B. Dimassimo⁶, R. Smith⁶, B. Baker⁶, F. Duff⁵, J. Drucker⁶, T. Matthews⁶, and S. Hopkins⁶for the T1249-101 Study Group
¹Univ. of North Carolina at Chapel Hill; ²Stanford Univ., Palo Alto, CA; ³Univ. of Alabama at Birmingham; ⁴IFDI, Tampa, FL; ⁵Roche, Inc., Nutley, NJ; and ⁶Trimeris, Inc., Durham, NC.

BACKGROUND: T-1249 is a peptide fusion inhibitor developed as a follow on compound to T-20. In laboratory and animal studies, T-1249 has demonstrated unique potency against a broad range of HIV-1, HIV-2, and SIV isolates, favorable PK characteristics, and a non-overlapping resistance profile with respect to T-20. We evaluated the safety, PK and antiviral activity of T-1249 in a phase I/II dose escalation study.

METHODS: We enrolled 72 HIV-1 positive, treatment experienced adults with no concomitant ARV therapy and plasma HIV RNA >5,000 c/mL. Patients received T-1249 monotherapy by SC injection for 14 days at doses ranging from 6.25 mg/day to 50 mg/day, on a once or twice daily regimen. PK were assessed after a single IV dose (day -7) and during SC dosing (days 0 and 7).

RESULTS: Dose-dependent decreases in HIV RNA were observed. On day 14, the median change from baseline ranged from -0.10 (6.25 mg/day) to -1.40 (50 mg/day) log₁₀ c/mL. The plasma half-life and bioavailability support once-daily dosing. AUC, C_max and C_min were dose dependent. Two serious AEs, possibly related to study drug, occurred: hypersensitivity reaction (oral ulcers, maculopapular rash, fever) and grade 4 neutropenia. Otherwise, no treatment-related, clinically important laboratory abnormalities occurred. Injection site reactions (pain, induration, erythema) were mild and reported in 40% of patients. No dose-limiting toxicity was identified; therefore, evaluation of higher doses is warranted.

CONCLUSIONS: These results indicate that 14-day T- 1249 monotherapy is well tolerated, has PK characteristics that support once daily dosing, and confers potent, dose-related suppression of plasma HIV RNA.

2001-02-04
14

Copyright © 2001 - Foundation for Retrovirology and Human Health. Reproduction of this abstract (other than one copy for personal reference) must be cleared through the Foundation for Retrovirology and Human Health. Licensed (AIDSLINE) from National Library of Medicine.